UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2004
| Shire Pharmaceuticals Group plc |
| (Exact name of registrant as specified in its charter) |
| England and Wales |
| (State or other jurisdiction of incorporation) |
| 0-29630 | 98-0359573 |
| (Commission File Number) | (IRS Employer Identification No.) |
| Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England | |
| (Address of principal executive offices) | (Zip code) |
| Registrant's telephone number, including area code | 44 1256 894 000 |
| (Former name or former address, if changed since last report) |
| Item 5. | Other Events |
Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and which is incorporated by reference herein. | |
| Item 7. | Financial Statements and Exhibits |
| (c) Exhibits. The following exhibit is filed herewith: | |
| 99.1 | Press Release dated August 12, 2004 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SHIRE PHARMACEUTICALS GROUP | |||
| PLC | |||
| By: | /s/ A C Russell | ||
| Name: | Angus Russell | ||
| Title: | Chief Financial Officer | ||
Dated: August 12, 2004
EXHIBIT INDEX
| Number | Description |
| 99.1 | Press Release dated August 12, 2004 |
